Pentixapharm Holding AG (FRA:PTP)

Market Cap	64.31M -18.9%
Revenue (ttm)	1.52M -63.6%
Net Income	-26.50M
EPS	-1.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,179
Average Volume	836
Open	2.715
Previous Close	2.775
Day's Range	2.305 - 3.670
52-Week Range	1.312 - 4.480
Beta	n/a
RSI	61.75
Earnings Date	Apr 15, 2026

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2019
• Employees: 64
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PTP

Financial Performance

In 2024, Pentixapharm Holding AG's revenue was 1.40 million, a decrease of -78.47% compared to the previous year's 6.51 million. Losses were -13.98 million, 82.9% more than in 2023.